2007 Fiscal Year Final Research Report Summary
Analyses for the enhancing methods of tumor vaccination therapy in cancer-bearing hosts
| Project/Area Number |
18591241
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | University of Yamanashi |
|---|
Principal Investigator |
SHIBAGAKI Naotaka University of Yamanashi, Dept of Research Interdisciplinary Graduate School of Medicine and Engineering, Associate Professor (40262662)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Keywords | Vaccine / Antigen-specific immune responses / Antigen presentation / Protein transduction |
|---|
| Research Abstract |
We previously have shown that nona-arginine (R9)-PTD induced efficient protein-antigen (Ag) transduction of dendritic cells (DCs) in vitro, resulting in the efficient induction of strong Ag-specific immune responses mediated by CD8+ and CD4+ T cells and in superior antitumor effects in vivo. In the present study, we investigated the immune responses caused by intradermal (i.d.) injections of R9-PTD-containing protein Ags without DC preparation. We found that i.d. injections of recombinant R9-ovalbumin fusion protein (rR9-OVA) into naive C57BL/6 mice elicited OVA-specific CTLs and produced IgG2-dominant immunoglobulin. The i.d. injections of rR9-OVA also induced inflammatory cell infiltrations containing neutrophils, monocytes, and lymphocytes, as well as inflammatory cytokine productions, such as IFN-gamma, IL-2, IP-10, with presenting SIINFEKL-epitopes on MHC class I molecules at the injection area. Intratumoral injections of rR9-OVA into EG.7-tumor mass significantly suppressed tumor growth, and these effects were completely abrogated by the depletion of CD8+ T cells. These results indicate that i.d. injections of rR9-containing immunogenic Ag simultaneously induce dual immunological effects: the induction of Tc1- and Th1-dominant immune responses, and the induction of inflammatory and CTL-mediated immune responses at the injection area by expressing Ag-epitopes onto MHC class I molecules as targets.
|
